4th Ophthalmic Drug Delivery Summit

The 4th Ophthalmic Drug Delivery Summit addresses innovations in ophthalmic drug delivery methods and devices, focusing on achieving minimally invasive, sustained-release solutions for treating eye diseases.

Topics

• Suprachoroidal Delivery in Gene Therapy to Capitalize on Ocular Anatomy
• Overcoming Hurdles in Ophthalmic Clinical Trial Design to Spearhead Development
• The State of Play for Ophthalmic Drug Delivery to the Retina
• Advancing Retinal Therapy With Sustained Release Implants to Reduce Treatment Frequency
• The Journey of Genentech’s Susvimo Port Delivery System’s from Challenges to FDA Reapproval
• Advancements in Large Volume Formulations & High Viscosity Injectable Drug Delivery
• Drug Delivery Mechanics for Extended Release Implants
• Establishing Robust Clinical Trial Design to Overcome Past Failings
• Overcoming Inflammatory Responses to Maximize Therapeutic Effect
• The Evolving Landscape of Regulatory Approvals for Combination Products
• Navigating the Safety Landscape of Novel Drug Delivery
• Advancing Drug Formulations & Combinations to Achieve Sustained Release
• Advancing Targeted, Compartmentalized & Long-Acting Depot Delivery: Synergistic Combination of Particulate Formulation & Suprachoroidal Route of Administration
• Enhancing Ocular Drug Delivery Through Combined Microparticles, Nanoparticles & Hydrogels
• Mastering Suprachoroidal Delivery to Increase Distribution & Durability
• Expanding the Potential of the Suprachoroidal Space in Retinal Therapy
• Considering Non-Invasive Administration of Medications for Retinal Diseases : a Mechanism of Action Perspective
• Comparing of Existing Ophthalmic Models Approaches to Supercharge Development
• Utilizing Preclinical & Computational Models for Predicting Human Ophthalmic Drug Behavior
• Delivery Effective Cell & Gene Therapies to the Eye to Halt Vision Loss
• Optimizing Current Suprachoroidal & Subretinal Delivery of AAV Gene Therapies
• Enhancing Cell & Gene Therapies With Advanced Hydrogel Platforms
• Disease Indication & Endpoint Selection for Ophthalmic Gene Therapy Trials to Unlock Optimal Results
• Innovations with Topical & Oral Medications & the Path to Regulatory Success
• Considering Systemic Administration of PPARalpha Agonist for the Treatment of Diabetic Retinopathy & AMD